SCOPUS 정보 검색 플랫폼

Volumn 11, Issue 5, 2009, Pages 791-795

Ziprasidone malate, a new trimorphic salt with improved aqueous solubility

Author keywords

[No Author keywords available]

Indexed keywords

EID: 65349185558 PISSN: 14668033 EISSN: 14668033 Source Type: Journal
DOI: 10.1039/b813401d Document Type: Article

Times cited : (23)

References (19)

2
- 0036093932
- C. F. Caley C. K. Cooper Ann. Pharmacother. 2002 36 839
- (2002) Ann. Pharmacother. , vol.36 , pp. 839
- Caley, C.F.¹ Cooper, C.K.²

3
- 65349175282
- F. R. Busch and C. A. Rose, Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1, 3-dihydro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist, US6110918, 2000
- (2000) Mesylate Trihydrate Salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1- piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (=Ziprasidone), Its Preparation and Its Use As Dopamine D2 Antagonist, US6110918
- Busch, F.R.¹ Rose, C.A.²

4
- 65349152697
- F. R. Busch and C. A. Rose, Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1, 3-dihydro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist, US6245765, 2001
- (2001) Mesylate Dihydrate Salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1- piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (=Ziprasidone), Its Preparation and Its Use As Dopamine D2 Antagonist, US6245765
- Busch, F.R.¹ Rose, C.A.²

5
- 65349165929
- G. K. Jain and M. K. Kondapaturu, Ziprasidone formulations, WO 2007102038, 2007
- (2007) Ziprasidone Formulations, WO 2007102038
- Jain, G.K.¹ Kondapaturu, M.K.²

7
- 65349140838
- Inclusion complexes of aryl-heterocyclic salts
- K. C. Johnson Y. Kim R. M. Shanker Inclusion complexes of aryl-heterocyclic salts PCT Int. Appl. 1997
- (1997) PCT Int. Appl.
- Johnson, K.C.¹ Kim, Y.² Shanker, R.M.³

8
- 39749187735
- R. Srivijaya P. Vishweshwar B. R. Sreekanth K. Vyas CrystEngComm 2008 10 283
- (2008) CrystEngComm , vol.10 , pp. 283
- Srivijaya, R.¹ Vishweshwar, P.² Sreekanth, B.R.³ Vyas, K.⁴

9
- 0042058435
- Wiley-VCH: Weinheim
- P. H. Stahl and C. G. Wermuth, Handbook of Pharmaceutical Salts, Wiley-VCH: Weinheim, 2002
- (2002) Handbook of Pharmaceutical Salts
- Stahl, P.H.¹ Wermuth, C.G.²

10
- 34548032742
- A. T. M. Serajuddin Adv. Drug Delivery Rev. 2007 59 603
- (2007) Adv. Drug Delivery Rev. , vol.59 , pp. 603
- Serajuddin, A.T.M.¹

11
- 65349140258
- EP08380116.7
- R. Barbas, A. Portell, R. Prohens, C. Puigjaner, P. Dalmases, New ziprasidone salt, EP08380116.7, 2008
- (2008) New Ziprasidone Salt
- Barbas, R.¹ Portell, A.² Prohens, R.³ Puigjaner, C.⁴ Dalmases, P.⁵

12
- 0031742447
- 1/a, a = 7.377(8), b = 8.038(3), c = 33.627(6)
- Y. Kim D. A. Oksanen W. Massefski J. F. Blake E. M. Duffy B. Chrunyk J. Pharm. Sci. 1998 87 1560
- (1998) J. Pharm. Sci. , vol.87 , pp. 1560
- Kim, Y.¹ Oksanen, D.A.² Massefski, W.³ Blake, J.F.⁴ Duffy, E.M.⁵ Chrunyk, B.⁶

13
- 0034345216
- R. J. Bastin M. J. Bowker B. J. Slater Org. Process. Res. Dev. 2000 4 427
- (2000) Org. Process. Res. Dev. , vol.4 , pp. 427
- Bastin, R.J.¹ Bowker, M.J.² Slater, B.J.³

14
- 0023032232
- P. L. Gould Int. J. Pharm. 1986 33 201
- (1986) Int. J. Pharm. , vol.33 , pp. 201
- Gould, P.L.¹

15
- 84921935631
- Clarendon Press, Oxford
- J. Bernstein, Polymorphism in Molecular Crystals, Clarendon Press, Oxford, 2002
- (2002) Polymorphism in Molecular Crystals
- Bernstein, J.¹

16
- 4344717272
- This rule states that if an endothermal transition (for a solid-state conversion) is observed at some temperature, it may be assumed that there is a transition point below it; i.e., the two forms are related enantiotropically
- D. Giron M. Mutz S. Garnier J. Therm. Anal. Cal. 2004 77 709
- (2004) J. Therm. Anal. Cal. , vol.77 , pp. 709
- Giron, D.¹ Mutz, M.² Garnier, S.³

17
- 0003973115
- A. Burger R. Ramberger Mikrochim. Acta I 1979 259 271
- (1979) Mikrochim. Acta i , pp. 259-271
- Burger, A.¹ Ramberger, R.²

18
- 0029871997
- A. Grunenberg J. O. Henck H. W. Siesler Int. J. Pharm. 1996 129 147
- (1996) Int. J. Pharm. , vol.129 , pp. 147
- Grunenberg, A.¹ Henck, J.O.² Siesler, H.W.³

19
- 28944454413
- We report solubilities after stirring saturated salts between 45 min to 1 h because we have observed that malate salts transform into the hydrated form (which is less soluble) when they are stirred in water for 30 h
- S. Desikan R. L. Parsons W. P. Davis J. E. Ward W. J. Marshall P. H. Toma Org. Process. Res. Dev. 2005 9 933
- (2005) Org. Process. Res. Dev. , vol.9 , pp. 933
- Desikan, S.¹ Parsons, R.L.² Davis, W.P.³ Ward, J.E.⁴ Marshall, W.J.⁵ Toma, P.H.⁶

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.